Annovis Bio

Annovis Bio is a late-stage clinical drug-platform company developing oral therapies for neurodegeneration, focused on Alzheimer's and Parkinson's disease. Its lead candidate, buntanetap (formerly posiphen, ANVS401), inhibits the translation of multiple neurotoxic proteins — APP and amyloid beta, tau, alpha-synuclein and TDP-43 — through a single RNA-targeting mechanism, an approach the company positions against single-target antibodies. The pivotal Phase 3 programme in early Alzheimer's disease has completed enrolment; database lock is guided to the fourth quarter of 2026 with a top-line readout in the first quarter of 2027, ahead of a potential New Drug Application. The company was founded in 2008, is headquartered in Malvern, Pennsylvania, and listed on the New York Stock Exchange in 2020.